Product Code: LI_161434 / A01115
The global defibrillators market was valued at $13,168 million in 2020, and is projected to reach $24,608.3 million by 2030, registering a CAGR of 6.6% from 2021 to 2030.
Defibrillation is a medical procedure used to treat life threatening conditions that affect the rhythm of the heart such as cardiac arrhythmia, ventricular fibrillation, and pulseless ventricular tachycardia. The procedure involves the delivery of an electric shock to the heart, which causes depolarization of the heart muscles and re-establishes normal conduction of the heart's electrical impulse. The device that delivers the therapeutic shock to the heart is called a defibrillator.
The defibrillators market is witnessing tremendous growth owing to technological advancements in the field of defibrillators, rise in prevalence of cardiac diseases, and rise in training and awareness programs among physician and researcher for defibrillators.
The major factors that drive the market include increase in adoption of technologically advanced medical devices, rise in demand for quality medical care, and high incidences of sudden cardiac arrest (SCA). In addition, the increase in R&D activities to develop medical devices and increase in number of key market players to manufacture advanced defibrillators across the globe are a few more factors that drive the growth of the defibrillators market. Moreover, promoting the innovation of the next-generation external defibrillators to improve safety and effectiveness of devices, identifying and addressing problems associated with devices by the Food and Drug Administration (FDA), and focusing on the treatment of SCA are anticipated to create lucrative opportunities for the growth of the defibrillators market.
However, lack of awareness about sudden cardiac arrest in developing nations are expected to hinder the growth of the defibrillators market during the forecast period. Moreover, limited reimbursements in developed nations and lack of infrastructure, particularly in developing and underdeveloped countries are also expected to hinder the market growth.
The defibrillators market in this report is studied on the basis of product, end user, and region. On the basis of product, the market is divided implantable defibrillators and external defibrillators. Implantable defibrillators are classified into transvenous implantable cardioverter defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillator (S-ICDs), and cardiac resynchronization therapy- defibrillator (CRT-D). External defibrillators are further classified as manual external defibrillator, automated external defibrillator (AEDs), and wearable cardioverter defibrillator (WCDs). As per end user, the market is segregated into hospitals, pre-hospital, public access market, alternative care, and home. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for the largest market share in the defibrillators market in 2020, and is expected to retain its dominance during the forecast period. This is primarily attributed to initiatives by key players for manufacturing of advanced defibrillator device, favorable regulations by government and private organizations, and technologically advanced healthcare facilities in the U.S. and Canada. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to development of healthcare infrastructure, high patient population, and prevalence of cardiac diseases.
The major players operating in the global defibrillators market are Asahi Kasei Corporation, Stryker Corporation, Biotronik SE & Co. KG, Boston Scientific Corporation, Philips Healthcare, LivaNova PLC, Medtronic plc, Cardiac Science Corporation, Nihon Kohden Corporation, and St. Jude Medical, Inc. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides in-depth analysis of the global defibrillators market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global defibrillators market growth.
KEY MARKET SEGMENTS
- By Product
- Implantable Defibrillators
- Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
- Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
- Cardiac Resynchronization Therapy- Defibrillator (CRT-D)
- External Defibrillators
- Manual External Defibrillator
- Automated External Defibrillator (AEDs)
- Wearable Cardioverter Defibrillator (WCDs)
- By End User
- Hospitals
- Pre-Hospitals
- Public Access Market
- Alternative Care
- Home
- By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Egypt
- Israel
- South Africa
- Rest of LAMEA
- List of key players profiled in the report:
- Asahi Kasei Corporation
- Stryker Corporation
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Philips Healthcare
- LivaNova PLC
- Medtronic plc
- Cardiac Science Corporation
- Nihon Kohden Corporation
- St. Jude Medical, Inc.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1.Primary Research
- 1.4.2.Secondary Research
- 1.4.3.Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1.Top Investment Pockets
- 3.2.2.Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1.Bargaining Power of Suppliers
- 3.3.2.Threat of New Entrants
- 3.3.3.Threat of Substitutes
- 3.3.4.Competitive Rivalry
- 3.3.5.Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1.Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Product Type
- 4.2.Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
- 4.2.1.Key Market Trends, Growth Factors and Opportunities
- 4.2.2.Market Size and Forecast, By Region
- 4.2.3.Market Share Analysis, By Country
- 4.3.Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
- 4.3.1.Key Market Trends, Growth Factors and Opportunities
- 4.3.2.Market Size and Forecast, By Region
- 4.3.3.Market Share Analysis, By Country
- 4.4.Cardiac Resynchronization Therapy Defibrillator (CRT-D)
- 4.4.1.Key Market Trends, Growth Factors and Opportunities
- 4.4.2.Market Size and Forecast, By Region
- 4.4.3.Market Share Analysis, By Country
CHAPTER 5: IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Region
- 5.2.North America
- 5.2.1.Key Market Trends and Opportunities
- 5.2.2.Market Size and Forecast, By Product Type
- 5.2.3.Market Size and Forecast, By Country
- 5.2.4.United States Implantable Defibrillators Market
- 5.2.4.1.Market Size and Forecast, By Product Type
- 5.2.5.Canada Implantable Defibrillators Market
- 5.2.5.1.Market Size and Forecast, By Product Type
- 5.2.6.Mexico Implantable Defibrillators Market
- 5.2.6.1.Market Size and Forecast, By Product Type
- 5.3.Europe
- 5.3.1.Key Market Trends and Opportunities
- 5.3.2.Market Size and Forecast, By Product Type
- 5.3.3.Market Size and Forecast, By Country
- 5.3.4.France Implantable Defibrillators Market
- 5.3.4.1.Market Size and Forecast, By Product Type
- 5.3.5.Germany Implantable Defibrillators Market
- 5.3.5.1.Market Size and Forecast, By Product Type
- 5.3.6.Italy Implantable Defibrillators Market
- 5.3.6.1.Market Size and Forecast, By Product Type
- 5.3.7.Spain Implantable Defibrillators Market
- 5.3.7.1.Market Size and Forecast, By Product Type
- 5.3.8.U.K Implantable Defibrillators Market
- 5.3.8.1.Market Size and Forecast, By Product Type
- 5.3.9.Rest Of Europe Implantable Defibrillators Market
- 5.3.9.1.Market Size and Forecast, By Product Type
- 5.4.Asia-Pacific
- 5.4.1.Key Market Trends and Opportunities
- 5.4.2.Market Size and Forecast, By Product Type
- 5.4.3.Market Size and Forecast, By Country
- 5.4.4.China Implantable Defibrillators Market
- 5.4.4.1.Market Size and Forecast, By Product Type
- 5.4.5.Japan Implantable Defibrillators Market
- 5.4.5.1.Market Size and Forecast, By Product Type
- 5.4.6.India Implantable Defibrillators Market
- 5.4.6.1.Market Size and Forecast, By Product Type
- 5.4.7.South Korea Implantable Defibrillators Market
- 5.4.7.1.Market Size and Forecast, By Product Type
- 5.4.8.Australia Implantable Defibrillators Market
- 5.4.8.1.Market Size and Forecast, By Product Type
- 5.4.9.Rest of Asia Pacific Implantable Defibrillators Market
- 5.4.9.1.Market Size and Forecast, By Product Type
- 5.5.LAMEA
- 5.5.1.Key Market Trends and Opportunities
- 5.5.2.Market Size and Forecast, By Product Type
- 5.5.3.Market Size and Forecast, By Country
- 5.5.4.Brazil Implantable Defibrillators Market
- 5.5.4.1.Market Size and Forecast, By Product Type
- 5.5.5.South Africa, Implantable Defibrillators Market
- 5.5.5.1.Market Size and Forecast, By Product Type
- 5.5.6.Saudi Arabia Implantable Defibrillators Market
- 5.5.6.1.Market Size and Forecast, By Product Type
- 5.5.7.Rest of LAMEA Implantable Defibrillators Market
- 5.5.7.1.Market Size and Forecast, By Product Type
CHAPTER 6: COMPANY PROFILES
- 6.1.Abbott Laboratories
- 6.1.1.Company Overview
- 6.1.2.Key Executives
- 6.1.3.Company snapshot
- 6.1.4.Operating business segments
- 6.1.5.Product portfolio
- 6.1.6.Business Performance
- 6.1.7.Key Strategic Moves and Developments
- 6.2.Biotronik Schweiz Ag
- 6.2.1.Company Overview
- 6.2.2.Key Executives
- 6.2.3.Company snapshot
- 6.2.4.Operating business segments
- 6.2.5.Product portfolio
- 6.2.6.Business Performance
- 6.2.7.Key Strategic Moves and Developments
- 6.3.Boston Scientific Corporation
- 6.3.1.Company Overview
- 6.3.2.Key Executives
- 6.3.3.Company snapshot
- 6.3.4.Operating business segments
- 6.3.5.Product portfolio
- 6.3.6.Business Performance
- 6.3.7.Key Strategic Moves and Developments
- 6.4.FUKUDA DENSHI CO. Ltd
- 6.4.1.Company Overview
- 6.4.2.Key Executives
- 6.4.3.Company snapshot
- 6.4.4.Operating business segments
- 6.4.5.Product portfolio
- 6.4.6.Business Performance
- 6.4.7.Key Strategic Moves and Developments
- 6.5.IMRICOR MEDICAL SYSTEMS
- 6.5.1.Company Overview
- 6.5.2.Key Executives
- 6.5.3.Company snapshot
- 6.5.4.Operating business segments
- 6.5.5.Product portfolio
- 6.5.6.Business Performance
- 6.5.7.Key Strategic Moves and Developments
- 6.6.Koninklijke Philips N.V.
- 6.6.1.Company Overview
- 6.6.2.Key Executives
- 6.6.3.Company snapshot
- 6.6.4.Operating business segments
- 6.6.5.Product portfolio
- 6.6.6.Business Performance
- 6.6.7.Key Strategic Moves and Developments
- 6.7.LivaNova PLC
- 6.7.1.Company Overview
- 6.7.2.Key Executives
- 6.7.3.Company snapshot
- 6.7.4.Operating business segments
- 6.7.5.Product portfolio
- 6.7.6.Business Performance
- 6.7.7.Key Strategic Moves and Developments
- 6.8.Medtronic Plc.
- 6.8.1.Company Overview
- 6.8.2.Key Executives
- 6.8.3.Company snapshot
- 6.8.4.Operating business segments
- 6.8.5.Product portfolio
- 6.8.6.Business Performance
- 6.8.7.Key Strategic Moves and Developments
- 6.9.Microport Scientific Corp
- 6.9.1.Company Overview
- 6.9.2.Key Executives
- 6.9.3.Company snapshot
- 6.9.4.Operating business segments
- 6.9.5.Product portfolio
- 6.9.6.Business Performance
- 6.9.7.Key Strategic Moves and Developments
- 6.10.Nohen Kohden Corporation
- 6.10.1.Company Overview
- 6.10.2.Key Executives
- 6.10.3.Company snapshot
- 6.10.4.Operating business segments
- 6.10.5.Product portfolio
- 6.10.6.Business Performance
- 6.10.7.Key Strategic Moves and Developments